Understood, I responded elsewhere that I read the Lowe article as talking about conceptual advances (ACE, HMG CoA), but I realize he's mixing both erstwhile unt

Understood, I responded elsewhere that I read the Lowe article as talking about conceptual advances (ACE, HMG CoA), but I realize he's mixing both erstwhile untreated indications as well as biosimilars.